Thomas O. Daniel has been the Executive Chairman of Vividion Therapeutics, a privately held biotechnology company, since February 2017 and Executive Director of Catalysis Advisors, a biotechnology consulting firm, since August 2016. Dr. Daniel was previously Celgene Corporation’s Chairman of Research from January 2016 until June 2016, President of Research and Early Development from December 2006 to January 2016, and Executive Vice President and President of Research and Early Development from February 2012 until July 2014. Prior to joining Celgene, Dr. Daniel served as the Chief Scientific Officer and director at Ambrx Inc., a biotechnology company focused on discovering and developing protein-based therapeutics. Prior to Ambrx, Dr. Daniel served as Vice President of Research at Amgen Inc., where he was research site head of Amgen Washington and therapeutic area head of inflammation. Prior to Amgen’s acquisition of Immunex, Dr. Daniel served as Senior Vice President of Discovery Research at Immunex. Dr. Daniel has been a member of the therapeutic advisory board of aTyr Pharma, Inc. and is a director of FerruMax Pharmaceuticals and PharmAkea Therapeutics, privately-held biotechnology companies. Dr. Daniel was also formerly a director of Epizyme, Inc. Dr. Daniel serves as a member of the Biomedical Science Advisory Board of Vanderbilt University Medical Center and the Biomedical Advisory Council of PhRMA. A nephrologist and former academic investigator, Dr. Daniel was previously the K.M. Hakim Professor of Medicine and Cell Biology at Vanderbilt University, and Director of the Vanderbilt Center for Vascular Biology. Dr. Daniel received a B.A. from the Southern Methodist University in Texas in 1974 and an M.D. from the University of Texas, Southwestern, in 1978, and completed medical residency at Massachusetts General Hospital.